Company: TYRA
Filing Date: 2025-04-18
Form Type: DEF 14A
Source: 0001193125-25-085709
Chunk: 54

Company: Tyra Biosciences, Inc.
Filing Date: 2025-04-18
Form: DEF 14A
Chunk 54
---
 of the stock options, which will offset advisory fees owed by the Fund, the Nexus Fund and the Account. Mr. Simson therefore disclaims beneficial ownership of any stock options and underlying Common Stock. |

| (16) | Consists of 115,067 shares of Common Stock underlying stock options held by Mr. Verjee that are exercisable within 60 days of March 31, 2025. |

| (17) | Includes the shares described in footnotes 4 and 8 through 16, 14,087 shares of our Common Stock held directly by Alan Fuhrman and 260,758 shares of Common Stock underlying stock options held by Mr. Fuhrman that are exercisable within 60 days of March 31, 2025. |

Certain Relationships and Related Person Transactions The following is a summary of transactions entered into or existing since January 1, 2023 to which we have been a party in which the amount involved exceeded or will exceed $120,000 (or, if less, 1% of the average of our total assets at year-endfor the last two completed fiscal years), and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under “Executive and Director Compensation.” We also describe below certain other transactions with our directors, executive officers and stockholders. Investor Agreements We entered into an amended and restated investors’ rights agreement in March 2021 (the “IRA”), with the holders of our convertible preferred stock and certain holders of our Common Stock, including the holders of more than 5% of our capital stock listed above as well as entities with which certain of our directors are affiliated. This agreement provides for certain rights relating to the registration of their shares of Common Stock issued upon conversion of their convertible preferred stock and certain additional covenants made by us. 2024 Private Placement On February 6, 2024, we completed a private placement of (i) 9,286,023 shares of Common Stock at a price of $13.01 per share of Common Stock and (ii) pre-fundedwarrants to purchase up to 6,087,230 shares of Common Stock, at a price of $13.009 per pre-fundedwarrant, for